Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...

Drug is also being tested as a treatment for the skin condition atopic dermatitis, Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing ...

The US Food and Drug Administration (FDA ... Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG’s Avastin (bevacizumab) and Bristol-Myers Squibb ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President ...

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, and are hoping that a newly-approved long-acting drug can ...